Beijing Biostar Pharmaceuticals Co Ltd
Beijing Biostar Pharmaceuticals Co Ltd is a pharmaceutical company engaged in the research, development, production, and sale of biopharmaceutical products.
Business. Beijing Biostar Pharmaceuticals Co Ltd (2563.HK) is a pharmaceutical company headquartered in Beijing that operates within the healthcare sector. The firm is primarily listed on the Hong Kong Stock Exchange. As specific segment and geographic data are not provided, the company is described at the industry level as a participant in pharmaceuticals and medical research. Its business model centers on product sales within the pharmaceutical industry.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Beijing Biostar Pharmaceuticals Co Ltd (2563.HK) is a pharmaceutical company headquartered in Beijing that operates within the healthcare sector. The firm is primarily listed on the Hong Kong Stock Exchange. As specific segment and geographic data are not provided, the company is described at the industry level as a participant in pharmaceuticals and medical research. Its business model centers on product sales within the pharmaceutical industry.
The company has a market capitalization of 1.53 billion CNY, with a market price of 4.2 CNY per share. The shares outstanding are 364,588,000 for both basic and diluted shares, indicating no dilution from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability metrics are not available in the valuation snapshot, but the last actual earnings per share (EPS) reported was -0.41 CNY, indicating a loss per share. The company's revenue for the latest period was 71,866,000 CNY. Analysts have provided a uniform price target of 35.85 CNY, which is significantly higher than the current market price, suggesting a potential for substantial upside.
The company's revenue concentration and geographic exposure are not disclosed in the available data. However, as a pharmaceutical company, it is likely to have a diversified customer base and may operate in multiple regions. The lack of segment data limits the ability to assess the company's exposure to different markets or product lines.
The company's growth trajectory is unclear due to the lack of historical revenue data. The last actual revenue was 71,866,000 CNY, but without prior periods, it is difficult to determine the growth rate. Analysts have set a high price target, which may indicate expectations of future growth, but this is not supported by current financial performance.
The company faces low dilution risk, as there is no evidence of dilutive instruments or recent equity issuances. However, the lack of balance-sheet data and going-concern language in source documents raises concerns about the company's financial stability and liquidity.
Recent events and filings are not detailed in the available data. The company's financial performance, as reflected in the last actual EPS and revenue, suggests a challenging operating environment. Analysts have set a high price target, but this is not supported by current financial metrics.
- The company is currently trading at a significant discount to the analyst price target of 35.85 CNY.
- The company reported a loss per share of -0.41 CNY in the latest period.
- Analysts have provided a uniform price target, indicating a consensus on the company's potential.
- The company has no dilution from stock options or convertible securities.
- Liquidity risk could not be assessed due to the absence of balance-sheet data.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥71.9M, +7,8% YoY; Operating income +24,2% YoY.
- ▍Revenue ¥71.9M, +7,8% YoY
- ▍Operating income +24,2% YoY
- ▍Net income +24,2% YoY
- ▍Free cash flow +15,5% YoY
- ▍Net margin -200.1%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Beijing Biostar Pharmaceuticals Co Ltd Market data — financials · 2026-05-26
- Beijing Biostar Pharmaceuticals Co Ltd Market data — analyst estimates · 2026-05-26